Transitional cell cancer of renal pelvis and ureter metastatic – Diagnostics – Overview of Information and Clinical Research

Diagnosing metastatic transitional cell cancer of the renal pelvis and ureter is a multi-step process that combines physical exams, imaging tests, and laboratory analyses to understand how far the cancer has spread and help doctors plan the best approach to treatment.

Introduction: Who Should Seek Diagnostics

People who notice certain warning signs should speak with their doctor about getting tested for transitional cell cancer of the renal pelvis and ureter. The most common early symptom is blood in the urine, which may appear pink, red, or brown. This symptom deserves attention even if it comes and goes, because cancer can cause bleeding that stops temporarily but returns later.^[1]

Other symptoms that should prompt a visit to your healthcare provider include pain in your back or side, especially between your ribs and hips, as well as unexplained weight loss, ongoing fatigue, or frequent urination that feels uncomfortable or painful. Sometimes you might feel a lump or mass in the area of your kidney when you touch your side or back.^[2]

This type of cancer is more commonly diagnosed in adults over age 65, and it affects men more often than women. People who have had bladder cancer in the past face a higher risk of developing transitional cell cancer in the upper urinary tract, so they should be especially alert to these symptoms. Smokers and people who work with certain chemicals used in manufacturing dyes, rubber, leather, paint, or textiles also have an increased risk and should pay close attention to any changes in their urinary health.^[1]^[2]

When the cancer has already spread to other parts of the body, which doctors call metastatic disease, additional symptoms may appear depending on where the cancer has traveled. Lung metastases might cause breathing problems or persistent cough, while bone metastases could create pain in specific areas. Liver metastases sometimes lead to yellowing of the skin or eyes. These symptoms make early diagnosis even more important, as catching the disease before it spreads greatly improves treatment options.^[8]

Diagnostic Methods for Identifying the Disease

The journey to diagnosis typically begins with a visit to your general practitioner, who will perform a physical examination and ask detailed questions about your symptoms and medical history. If your doctor suspects cancer of the renal pelvis or ureter, they will likely refer you to a specialist called a urologist, who focuses on diseases of the urinary system.^[1]

Urine Tests

One of the first diagnostic steps involves testing your urine. A urinalysis checks for blood cells, proteins, and other substances that shouldn’t normally be present in large amounts. Your doctor may also order a special test to look for cancer cells in your urine sample under a microscope. This examination, called urine cytology, can sometimes detect abnormal cells that have shed from the lining of the renal pelvis or ureter. However, these tests alone cannot provide a definitive diagnosis, so additional testing is nearly always necessary.^[5]^[17]

Blood Tests

Blood tests help doctors assess your overall health and kidney function. These tests measure levels of waste products that healthy kidneys normally filter out of the blood. When kidney function is compromised by cancer or other problems, these waste products build up to higher than normal levels. Blood tests also provide important information about whether you’re healthy enough for certain treatments, especially chemotherapy, which can be hard on the kidneys.^[1]

Imaging Tests

Imaging tests create detailed pictures of the inside of your body and are essential for diagnosing transitional cell cancer. A CT urogram, also called an intravenous pyelogram or IVP, is one of the most common imaging tests for this type of cancer. During this test, a special dye called contrast medium is injected into your vein. The dye travels through your bloodstream to your kidneys, renal pelvis, ureters, and bladder, making these structures show up clearly on X-ray or CT scan images. This test helps doctors see tumors, blockages, or other abnormalities in the urinary tract.^[5]^[17]

A standard CT scan of your chest may also be performed to check whether cancer has spread to your lungs. CT scans use X-rays taken from different angles and combine them with computer processing to create cross-sectional images of your body. This technology allows doctors to see small tumors that might not be visible on regular X-rays.^[1]

Other imaging tests that may be used include ultrasound, which uses sound waves to create pictures of internal organs, and MRI scans, which use powerful magnets and radio waves instead of X-rays. PET scans, which show how tissues are functioning rather than just their structure, may be ordered if doctors need to determine whether cancer has spread to distant parts of the body.^[5]^[17]

⚠️ Important

Even though diagnostic tests involving contrast dye are very helpful, they carry a small risk for people with kidney problems or allergies to contrast materials. Always tell your doctor if you have kidney disease, diabetes, or have ever had an allergic reaction to contrast dye, so they can take appropriate precautions or choose alternative testing methods.

Scope Examinations

To look directly inside the urinary tract, doctors use instruments called scopes, which are thin tubes with a light and camera attached. A cystoscopy allows the doctor to examine the inside of your bladder by passing the scope through the urethra. This procedure is important because people with transitional cell cancer of the renal pelvis or ureter have a high chance of also developing bladder cancer, with rates ranging from 30% to 50%.^[3]^[9]

A ureteroscopy extends further up into the ureter and sometimes into the renal pelvis itself. During this procedure, the doctor can not only see tumors but also take small tissue samples called biopsies. However, getting accurate information about how deeply the cancer has invaded the wall of the ureter or renal pelvis remains challenging even with these advanced viewing techniques. The depth of cancer invasion is one of the most important factors affecting prognosis, but it’s difficult to assess precisely without removing the entire tumor.^[3]^[9]

Another type of scope examination, called percutaneous endoscopy or pyeloscopy, involves making a small cut in your side or back so the doctor can insert the scope directly into the renal pelvis. This approach may be used in specific situations when the doctor needs a better view of tumors located in the kidney’s collecting system.^[12]

Tissue Biopsy

A biopsy involves removing a small sample of tissue so it can be examined under a microscope by a specialist doctor called a pathologist. The pathologist looks at the cells to determine if they are cancerous and, if so, what grade they are. The grade describes how abnormal the cancer cells look compared to normal cells. Low-grade cancers have cells that look more normal and tend to grow slowly, while high-grade cancers have very abnormal-looking cells and usually grow more aggressively.^[3]^[9]

Biopsies can be taken during ureteroscopy or pyeloscopy procedures. The challenge is that small biopsy samples don’t always provide complete information about the cancer’s grade or how deeply it has grown into the tissue. Despite this limitation, biopsies remain an essential diagnostic tool because they provide the only definitive proof that cancer is present.^[3]^[9]

Diagnostics for Clinical Trial Qualification

Clinical trials test new treatments or combinations of treatments to find better ways to manage cancer. Each clinical trial has specific requirements, called eligibility criteria, that determine who can participate. These criteria exist to ensure patient safety and to make sure the study results are scientifically valid.

For metastatic transitional cell cancer of the renal pelvis and ureter, common diagnostic tests used to determine clinical trial eligibility include comprehensive staging scans to confirm that the cancer has spread beyond the original site. CT scans of the chest, abdomen, and pelvis are standard requirements, as trials need precise information about where the cancer has spread and how large the tumors are.^[1]

Blood tests measuring kidney function are particularly important for clinical trial qualification. Many cancer treatments, especially chemotherapy drugs that contain platinum compounds like cisplatin, are filtered through the kidneys and can cause kidney damage. Trials often require that participants have adequate kidney function before enrollment. This is typically measured by testing levels of a waste product called creatinine in the blood and calculating how efficiently the kidneys are filtering blood, a measurement called the glomerular filtration rate or GFR.^[12]

Other blood tests check your red blood cell count, white blood cell count, platelet count, and liver function. These tests help determine whether your body is strong enough to tolerate experimental treatments. Clinical trials may exclude people whose blood counts are too low or whose liver function is impaired, as these conditions could make treatment complications more likely.

Tissue samples from biopsies may need to be tested for specific biomarkers, which are molecules that provide information about the cancer’s characteristics. Some clinical trials only accept participants whose tumors have certain genetic changes or express particular proteins. For example, trials testing drugs that target specific growth pathways in cancer cells may require proof that your tumor has the molecular target the drug is designed to attack.

The performance status of the patient, which measures how well they can carry out daily activities, is another crucial factor. Doctors use standardized scales to rate whether someone is fully active, somewhat limited, or needs considerable assistance with self-care. Most clinical trials require participants to be relatively independent in their daily activities because the treatments being tested can be demanding on the body.

Documentation of previous treatments is also essential for clinical trial qualification. Trials often specify whether participants must be treatment-naive, meaning they haven’t received any cancer treatment yet, or whether they can have had previous treatments but those treatments must have failed or stopped working. The timeline since previous treatment may also matter, as some trials require a “washout period” during which no other cancer treatments are given.^[12]

⚠️ Important

Before surgery removes the kidney and ureter affected by cancer, that kidney is still functioning and contributing to your overall kidney function. Many clinical trials require adequate kidney function, which is why doctors sometimes recommend chemotherapy before surgery rather than after. This approach, called neoadjuvant chemotherapy, allows patients to receive platinum-based treatments while they still have two working kidneys, potentially making them eligible for more clinical trials and treatment options.

Prognosis and Survival Rate

Prognosis

The outlook for people with transitional cell cancer of the renal pelvis and ureter depends heavily on how deeply the cancer has grown into the tissue wall at the time of diagnosis. This factor, called the depth of infiltration, is the most important predictor of how the disease will progress. Cancers that remain superficial and confined to the inner lining have a much better prognosis than those that have invaded deeply through multiple layers of tissue.^[3]^[9]

The grade of the cancer cells also affects prognosis. Superficial tumors are usually well-differentiated, meaning their cells look relatively normal under the microscope and tend to behave less aggressively. In contrast, deeply invasive tumors are typically poorly differentiated, with cells that look very abnormal and grow rapidly.^[3]^[9]

When the cancer is caught early and remains in the renal pelvis or ureter without spreading, treatment is very effective. However, once the tumor penetrates through the wall of these structures or spreads to distant parts of the body, creating metastases, the chances of cure with currently available treatments become much lower.^[3]^[9]

An important consideration for long-term prognosis is the high risk of developing new cancers in other parts of the urinary tract. Between 2% and 4% of people with this cancer will develop another cancer in the opposite kidney’s urinary system. More significantly, 30% to 50% of people who have had upper tract transitional cell cancer will later develop bladder cancer. When the cancer involves both the renal pelvis and ureter, the likelihood of subsequent bladder cancer increases to 75%.^[3]^[9]

Survival Rate

For cancers caught at the earliest stages, when they are superficial and confined to the renal pelvis or ureter, more than 90% of patients can be cured. These excellent survival rates reflect how treatable the disease is when detected early.^[3]^[9]

When the cancer has grown deeper but remains confined within the renal pelvis or ureter, the five-year survival rate drops significantly. Patients with deeply invasive tumors that have not yet spread beyond the organ have only a 10% to 15% likelihood of cure.^[3]^[9]

Canadian statistics provide additional perspective on survival rates. For cancer of the ureter specifically, the five-year net survival rate is 46%, meaning that about 46% of people diagnosed will survive at least five years. Cancer statistics for the renal pelvis are grouped together with kidney cancer overall, showing a combined five-year net survival rate of 71%.^[24]

When looking at survival by grade and stage, the numbers tell a more detailed story. Low-grade cancer that hasn’t grown beyond the inner connective tissue layer has a 100% five-year survival rate. Cancer that is grade 1, 2, or 3 and remains only in the innermost lining has an 80% five-year survival rate. However, when high-grade cancer has grown into the wall of the pelvis, the five-year survival rate drops to between 20% and 30%. Once the cancer has grown completely through the renal pelvis into nearby areas, the five-year survival rate falls to just 5%.^[24]

It’s important to note that survival rates for cancer of the ureter tend to be approximately 10% to 20% lower than for similar grade and stage cancer in the renal pelvis, suggesting that location matters for outcomes.^[24]

Patients with tumors that have penetrated through the tissue wall or developed distant metastases usually cannot be cured with currently available forms of treatment. However, treatments can still help manage symptoms, slow disease progression, and improve quality of life even when cure is not possible.^[3]^[9]

#1 Clinical Trials Search in Europe